1. Home
  2. HXHX vs DRMA Comparison

HXHX vs DRMA Comparison

Compare HXHX & DRMA Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.

HXHX

Haoxin Holdings Limited Class A Ordinary Shares

HOLD

Current Price

$0.54

Market Cap

6.2M

Sector

Industrials

ML Signal

HOLD

Logo Dermata Therapeutics Inc.

DRMA

Dermata Therapeutics Inc.

HOLD

Current Price

$1.29

Market Cap

5.1M

Sector

Health Care

ML Signal

HOLD

Company Overview

Basic Information
Metric
HXHX
DRMA
Founded
2003
2014
Country
China
United States
Employees
85
9
Industry
Trucking Freight/Courier Services
Biotechnology: Pharmaceutical Preparations
Sector
Industrials
Health Care
Exchange
Nasdaq
Nasdaq
Market Cap
6.2M
5.1M
IPO Year
N/A
N/A

Fundamental Metrics

Financial Performance
Metric
HXHX
DRMA
Price
$0.54
$1.29
Analyst Decision
Strong Buy
Analyst Count
0
1
Target Price
N/A
$10.00
AVG Volume (30 Days)
790.5K
1.8M
Earning Date
05-20-2026
05-13-2026
Dividend Yield
N/A
N/A
EPS Growth
N/A
N/A
EPS
N/A
N/A
Revenue
N/A
N/A
Revenue This Year
N/A
N/A
Revenue Next Year
N/A
N/A
P/E Ratio
$1.96
N/A
Revenue Growth
N/A
N/A
52 Week Low
$0.33
$0.59
52 Week High
$2.15
$7.33

Technical Indicators

Market Signals
Indicator
HXHX
DRMA
Relative Strength Index (RSI) 60.69 46.54
Support Level $0.49 $1.13
Resistance Level $0.57 $1.84
Average True Range (ATR) 0.07 0.16
MACD 0.01 0.01
Stochastic Oscillator 82.64 23.01

Price Performance

Historical Comparison
HXHX
DRMA

About HXHX Haoxin Holdings Limited Class A Ordinary Shares

Haoxin Holdings Ltd is engaged in the logistics industry, including container provider of temperature-controlled truckload service and urban delivery services in China, freight forwarding, cold chain transportation and other businesses. The types of goods involved are all kinds of new energy materials that require low temperature, heat preservation, and constant temperature, electronic products, medicines, meat, fruits, vegetables and others.

About DRMA Dermata Therapeutics Inc.

Dermata Therapeutics Inc develops and commercializes dermatology products for the treatment of common skin conditions. It focuses on leveraging prior clinical and technical expertise to develop OTC treatments for conditions such as acne, psoriasis, rosacea, and seborrheic dermatitis. The company is currently developing a once-weekly acne treatment system that utilizes an active ingredient from the OTC monograph in combination with the company's Spongilla technology. It intends to apply its Spongilla technology platform across a range of dermatologic and aesthetic skin applications, including intradermal delivery of botulinum toxin. The company's operates in one segment, which is the business of developing, branding, marketing, and commercializing direct to consumer skincare products.

Share on Social Networks: